Paper Details

  1. Home
  2. Paper Details

C/EBPalpha reverses the anti-adipogenic effects of the HIV protease inhibitor nelfinavir.

Author: DowellPaul, LaneM Daniel

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Nelfinavir is an HIV protease inhibitor that can cause fat loss and insulin resistance. This study found that nelfinavir can inhibit the formation of fat cells, which may explain its side effects on fat metabolism.
Paper Details　
Original Abstract of the Article :
Nelfinavir and other HIV protease inhibitors effectively suppress morbidity and mortality in HIV-infected patients. However, therapeutic use of HIV protease inhibitors has been temporally associated with the development of a lipodystrophy/insulin resistance syndrome and some evidence suggests that H...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.bbrc.2004.11.169

データ提供：米国国立医学図書館（NLM）

Nelfinavir: A Desert Storm for Adipogenesis?

Nelfinavir, an HIV protease inhibitor, is a valuable tool for managing HIV infection. However, its use has been linked to a lipodystrophy/insulin resistance syndrome, suggesting potential adverse effects on fat metabolism. This study delves into the anti-adipogenic effects of nelfinavir, exploring its impact on adipocyte differentiation and triglyceride storage.

The researchers discovered that nelfinavir promotes triglyceride loss from differentiated adipocytes and inhibits preadipocyte differentiation. They also found that forced expression of C/EBPalpha, an adipogenic transcription factor, partially rescued the anti-adipogenic effects of nelfinavir. This suggests that nelfinavir may interfere with adipogenesis by antagonizing C/EBPalpha expression.

A Camel's Oasis of Adipogenesis Control?

The study's findings suggest that nelfinavir may contribute to the development of lipodystrophy by interfering with adipogenesis. This highlights the importance of monitoring fat metabolism and potential metabolic complications in patients receiving nelfinavir.

A Camel's Compass for HIV Treatment

This research underscores the need for a holistic approach to HIV management, considering the potential metabolic effects of medications. It is crucial to consult with a healthcare professional to monitor for metabolic complications and manage them appropriately.

Dr. Camel's Conclusion

This study explores the complex interplay between HIV protease inhibitors, fat metabolism, and the development of lipodystrophy. While nelfinavir is a valuable tool for HIV management, its potential impact on adipogenesis highlights the importance of comprehensive monitoring and personalized treatment strategies.

Date :
  1. Date Completed 2005-03-07
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15629151

DOI: Digital Object Identifier

10.1016/j.bbrc.2004.11.169

Related Literature

Article Analysis
・Effects of nelfinavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.